Kimura H, Yamaguchi Y
Department of Surgery, Institute of Pulmonary Cancer Research School of Medicine, Chiba University.
Nihon Geka Gakkai Zasshi. 1989 Sep;90(9):1459-62.
Adoptive immunotherapy using LAK cells and IL-2 was performed against stage III and IV primary lung cancer patients after surgery. A randomized controlled study consisting of control group A, chemotherapy (CDDP + VDS) group B and chemo-immunotherapy (CDDP+VDS, IL2+LAK cells) group C suggested better survival rate in the group C. Direct effects were studied against 8 recurrent or inoperable lung cancer cases. Complete response was obtained against a pleuritis and pericarditis carcinomatosa case when in vitro stimulated LAK cells (St-LAK) were administered locally. Partial response was observed against a inoperable case when LAK-BAI (bronchial arterial infusion) was combined with radiation therapy.
对III期和IV期原发性肺癌患者术后采用LAK细胞和白细胞介素-2进行过继性免疫治疗。一项随机对照研究，包括对照组A、化疗（顺铂+长春地辛）组B和化学免疫治疗（顺铂+长春地辛、白细胞介素2+LAK细胞）组C，结果表明C组生存率更高。对8例复发性或无法手术的肺癌病例研究了直接疗效。当局部给予体外刺激的LAK细胞（St-LAK）时，对1例癌性胸膜炎和心包炎病例获得了完全缓解。当LAK支气管动脉灌注（LAK-BAI）与放射治疗联合应用时，对1例无法手术的病例观察到部分缓解。
